Chengdu Knowledge Vision Technology Secures Tens of Millions RMB Series A Funding Led by Changrun Capital

On June 13, 2019, Arterial New Medicine (WeChat ID: biobeat1) learned at the earliest opportunity that Chengdu Zhishi Visual Technology Co., Ltd. announced the completion of a multi-million RMB equity financing round invested by Shenzhen Changrun Binglun Intelligent Manufacturing Industry Investment Enterprise (Limited Partnership), under Changrun Capital.

Knowledge Vision Technology, established in 2016, is a company specializing in medical artificial intelligence and digital pathology. It is committed to leveraging cutting-edge AI technologies—including machine vision, deep learning, and knowledge graphs—to provide smart healthcare services such as precision companion diagnostics and treatment regimen selection for malignant tumors.

Knowledge Vision is committed to building an intelligent cloud platform for the research and development of pathology AI applications. Version 1.0 of the system made its public debut at the Chinese Society of Pathology Annual Conference in October 2018, receiving unanimous acclaim from the industry and peers. By aggregating common clinical needs for AI-assisted pathological analysis, the platform standardizes and modularizes the technologies involved in pathology AI application development. It enables a full-process workflow encompassing data management, image annotation, algorithm development, and application deployment, while supporting qualitative, localizational, quantitative, visualized, and digital analysis of histopathology. The platform effectively addresses key pain points in current pathology AI R&D, such as high technical barriers, substantial hardware investments, and elevated costs for communication and data annotation. It empowers pathologists by facilitating pathology AI research without the need for large-scale coding.

Currently, this platform primarily serves the field of new drug development, providing researchers with pathological quantitative analysis based on techniques such as histomorphology, immunohistochemistry, and in situ hybridization. By delivering more precise results from pathological quantitative analysis, the system offers intelligent decision support to new drug developers, helping determine correlations between pathological data features and prognosis, improving the efficiency and progress of quantitative analysis of pathological sections, and ensuring consistency in histopathological analysis.

Meanwhile, the system can also be used for subject screening and determination of companion diagnostic cutoff values, enabling visualization, traceability, quality assurance, and quality control throughout the pathological analysis process. This helps reduce drug development costs and clinical trial risks, thereby enhancing the market competitiveness of investigational drugs. Furthermore, by leveraging data encryption and authorized access mechanisms, the platform ensures user data security while facilitating multi-party collaboration and data sharing.

Changrun Capital targets the technological high ground of next-generation technologies, focusing on investments in high-end manufacturing, information technology, and the internet sector. In recent years, Changrun Capital has made strategic in-depth investments in frontier technology, backing industry benchmark enterprises such as Kaipu Cloud, United Winners Laser, Hanshow Technology, and Shuwei Technology. This investment in Zhishi Vision marks another significant move by Changrun Capital in the field of artificial intelligence. Changrun Capital will work hand in hand with the company to advance the intelligent and quantitative development of pathology research, contributing to the growth of smart healthcare in China.